A recent report consolidated advances in understanding CAR‑T associated neurotoxicity, outlining cellular and molecular mechanisms implicated in immune effector cell‑associated neurotoxicity syndrome (ICANS) and summarizing emerging mitigation strategies. The review synthesizes clinical observations, biomarker work, and preclinical models to guide risk stratification and management protocols. Authors recommend standardizing neurotoxicity endpoints in trials and exploring targeted interventions to reduce neurologic morbidity.